SCHEMBL41953

SCHEMBL41953

O=C1[C@H]2CC=CC[C@H]2C(=O)N1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
LMNA P02545 2/20 0.47
TSHR P16473 2/20 0.47
KMT2A Q03164 2/20 0.47
HSD17B10 Q99714 2/20 0.47
TP53 P04637 2/20 0.47
HPGD P15428 2/20 0.47
CYP3A4 P08684 1/20 0.47
ALOX15 P16050 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
HIF1A Q16665 1/20 0.47
CA9 Q16790 3/20 0.46
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
NPSR1 Q6W5P4 2/20 0.45
TDP1 Q9NUW8 4/20 0.44
POLB P06746 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17970089 1.00 ALDH1A1 (0.47) ALDH1A1LMNATSHRKMT2AHSD17B10
SCHEMBL16607543 1.00 ALDH1A1 (0.47) ALDH1A1LMNATSHRKMT2AHSD17B10
SCHEMBL2661927 0.74 NPSR1 (0.50) ALDH1A1LMNATSHRKMT2AHSD17B10
SCHEMBL21449886 0.74 ALDH1A1 (0.47) ALDH1A1LMNATSHRKMT2AHSD17B10
SCHEMBL676110 0.74 NPSR1 (0.50) ALDH1A1LMNATSHRKMT2AHSD17B10
SCHEMBL3108916 0.74 ALDH1A1 (0.47) ALDH1A1LMNATSHRKMT2AHSD17B10
SCHEMBL8249002 0.74 ALDH1A1 (0.39) ALDH1A1LMNATSHRKMT2AHSD17B10
SCHEMBL8620015 0.73 ALDH1A1 (0.53) ALDH1A1LMNATSHRKMT2AHSD17B10
SCHEMBL17532418 0.72 ALDH1A1 (0.57) ALDH1A1LMNATSHRKMT2AHSD17B10
SCHEMBL13169805 0.72 CA9 (0.44) ALDH1A1LMNATSHRKMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114805043-A Preparation method and system of cyclopentanone 中国石油化工股份有限公司 2022-07-29 CN claimed
CN-114805042-A Method and system for preparing cyclopentanone and application thereof 中国石油化工股份有限公司 2022-07-29 CN claimed
US-20250059191-A1 CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF MEIJI SEIKA PHARMA CO., LTD. (JP) 2025-02-20 US disclosed
US-12221443-B2 Crystalline forms of diazabicyclooctane derivative and production process thereof MEIJI SEIKA PHARMA CO., LTD. (JP) 2025-02-11 US disclosed
US-20220348578-A1 CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF MEIJI SEIKA PHARMA CO., LTD. (JP) 2022-11-03 US disclosed
US-11414417-B2 Crystalline forms of diazabicyclooctane derivative and production process thereof MEIJI SEIKA PHARMA CO., LTD. (JP) 2022-08-16 US disclosed
CN-114805043-A Preparation method and system of cyclopentanone 中国石油化工股份有限公司 2022-07-29 CN disclosed
CN-114805042-A Method and system for preparing cyclopentanone and application thereof 中国石油化工股份有限公司 2022-07-29 CN disclosed
CN-114057620-A Method and system for preparing hydrogen peroxide cyclopentylbenzene by cyclopentene 中国石油化工股份有限公司 2022-02-18 CN disclosed
US-11213804-B2 Dehydrogenation catalysts and methods of making and using the same EXXONMOBIL CHEMICAL PATENTS INC. (US) 2022-01-04 US disclosed
CN-113698332-A Method for preparing hydrogen peroxide cyclopentylbenzene from cyclopentylbenzene 中国石油化工股份有限公司 2021-11-26 CN disclosed
US-20030176733-A1 Method for oxidizing hydrocarbons CREAVIS GESELLSCHAFT FUER TECHNOLOGIE UND INNOVATION MBH (DE) 2003-09-18 US disclosed
US-20030083527-A1 Method for producing aromatic alcohols, especially phenol CREAVIS GESELLSCHAFT FUER TECHNOLOGY UND INNOVATION MBH (DE) 2003-05-01 US disclosed
US-6316639-B1 REACTING DICARBOXYLIC ACIDS OR ANHYDRIDES WITH A SALT OF HYDROXYL-AMINE IN SOLUTION SELECTED FROM HYDROXYLAMINE SULFATE, HYDROXYLAMINE NITRATE, HYDROXYLAMINE ACETATE, HYDROXYLAMINE TETRAFLUOROBORATE, HYDROXYLAMINE PHOSPHATE Consortium für elektrochemische Industrie GmbH (DE) 2001-11-13 US disclosed
US-6297403-B1 OXIDATION OF A (DI)ARYL METHANE OR METHYLENE DERIVATIVE IN PRESENCE OF AN AMINE OXIDE OR HYDROXYAMINE DERIVATIVE MEDIATOR; BY-PRODUCT INHIBITION Consortium für elektrochemische Industrie GmbH (DE) 2001-10-02 US disclosed
US-6242245-B1 DELIGNIFICATION BY ADDING SUSPENSION OF LACCASE, OXIDANT, MEDIATOR SUCH AS VIOLURIC ACID, AND XYLANASE TO AQUEOUS SUSPENSION OF LIGNIN MATERIAL AND MIXING; MEDIATOR DOES NOT DEACTIVATE ENZYME Consortium für elektrochemische Industrie GmbH (DE) 2001-06-05 US disclosed
US-6187170-B1 SYSTEM FOR THE ELECTROCHEMICAL CLEAVAGE OF COMPOUNDS WHICH INCLUDES A MEDIATOR AND AT LEAST TWO ELECTRODES FOR THE ELECTROCHEMICAL ACTIVATION OF THE MEDIATOR Consortium für elektrochemische Industrie GmbH (DE) 2001-02-13 US disclosed
US-6169213-B1 REACTING A HETEROARYL METHANOL WITH AN OXIDANT AND A MEDIATOR CONTAINING AMINO OXIDE GROUP TO FORM HETEROARYL ALDEHYDE OR A HETEROARYL KETONE Consortium f{umlaut over (u)}r elektrochemische Industrie GmbH (DE) 2001-01-02 US disclosed
US-6069282-A REACTION OF VINYL-, ALKYNYL- OR ARYL-METHANOLS WITH THE AID OF A MEDIATOR AND AN OXIDANT, WHEREIN THE MEDIATOR IS SELECTED FROM THE GROUP OF THE ALIPHATIC, CYCLOALIPHATIC, HETEROCYCLIC OR AROMATIC NO OR NOH CONTAINING COMPOUNDS CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) 2000-05-30 US disclosed
US-6023000-A Process for the preparation of aldehydes and ketones Consortium fur elektrochemisch Industrie GmbH (DE) 2000-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348578-A1 CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF CCNA1, RCC1, DDT ALDH1A1 1981/4885LMNA 1261/4885TSHR 3422/4885
US-20250059191-A1 CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF CCNA1, RCC1, DDT ALDH1A1 1981/4885LMNA 1261/4885TSHR 3422/4885
US-20030176733-A1 Method for oxidizing hydrocarbons CBR1, CBR3, SCO2 ALDH1A1 891/4885LMNA 1581/4885TSHR 2242/4885
US-11213804-B2 Dehydrogenation catalysts and methods of making and using the same IDH2, ADH4, IDH1 ALDH1A1 245/4885LMNA 2533/4885TSHR 3911/4885
US-12221443-B2 Crystalline forms of diazabicyclooctane derivative and production process thereof CCNA1, RCC1, DDT ALDH1A1 1981/4885LMNA 1261/4885TSHR 3422/4885
US-20030083527-A1 Method for producing aromatic alcohols, especially phenol CYP2E1, AOC2, ADH1C ALDH1A1 330/4885LMNA 762/4885TSHR 1479/4885
US-11414417-B2 Crystalline forms of diazabicyclooctane derivative and production process thereof CCNA1, RCC1, DDT ALDH1A1 1981/4885LMNA 1261/4885TSHR 3422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.